ORIC-114 for Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests ORIC-114, a new oral medicine for advanced cancers. It targets proteins that help cancer grow, including in the brain, and is for patients who need new treatment options.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Who Is on the Research Team?
Pratik S. Multani, MD, MS
Principal Investigator
ORIC Pharmaceuticals
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors that have specific changes in genes called EGFR or HER2. Participants must have tried standard treatments without success and be able to undergo a biopsy. They should not have serious lung conditions, active gastrointestinal diseases, recent heart issues, known infections like hepatitis B or C, HIV, or any uncontrolled medical conditions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation (Part I)
ORIC-114 is administered as a single agent to determine the recommended Phase 2 dose (RP2D) and maximum tolerated dose (MTD)
Dose Optimization (Part II)
Dose optimization to establish the RP2D and evaluate antitumor activity of ORIC-114
Combination Dose Escalation (Part III)
ORIC-114 is administered in combination with chemotherapy (carboplatin-pemetrexed) to establish the RP2D and/or MTD
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ORIC-114
Find a Clinic Near You
Who Is Running the Clinical Trial?
ORIC Pharmaceuticals
Lead Sponsor